CN Patent

CN102475706A — 一种供注射用盐酸兰地洛尔药物组合物及其制备方法

Assigned to Tianjin Hankang Pharmaceutical Biotechnology Co Ltd · Expires 2012-05-30 · 14y expired

What this patent protects

本发明公开了一种含有盐酸兰地洛尔活性成分的注射用药物组合物及其制备方法，其特征在于，各组分的组成及配比为：兰地洛尔50-200mg，依地酸钙钠2-8mg，乳糖100-400mg。本发明的注射用盐酸兰地洛尔冻干制剂具有良好的药物稳定性，临床使用和运输都很方便，该制剂专供临床手术时心动过速性心律失常（心房纤维性颤动、心房扑动及窦性心动过速）的紧急治疗，本发明提供了制备方法。

USPTO Abstract

本发明公开了一种含有盐酸兰地洛尔活性成分的注射用药物组合物及其制备方法，其特征在于，各组分的组成及配比为：兰地洛尔50-200mg，依地酸钙钠2-8mg，乳糖100-400mg。本发明的注射用盐酸兰地洛尔冻干制剂具有良好的药物稳定性，临床使用和运输都很方便，该制剂专供临床手术时心动过速性心律失常（心房纤维性颤动、心房扑动及窦性心动过速）的紧急治疗，本发明提供了制备方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN102475706A
Jurisdiction
CN
Classification
—
Expires
2012-05-30
Drug substance claim
No
Drug product claim
No
Assignee
Tianjin Hankang Pharmaceutical Biotechnology Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.